IMVT Jan 2026 60.000 call
| Previous Close | 2.0700 |
| Open | 2.0600 |
| Bid | 0.6000 |
| Ask | 4.3000 |
| Strike | 60.00 |
| Expire Date | 2026-01-16 |
| Day's Range | 2.0600 - 2.0700 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 208 |
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
Insider MonkeyShould You Hold Immunovant (IMVT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
ZacksHere's Why You Should Add Immunovant (IMVT) to Your Portfolio
Immunovant's (IMVT) late-stage studies evaluating its lead candidate, batoclimab, for various autoimmune indications are progressing well. Several data readouts are expected in 2024 and 2025.
